Suppr超能文献

基于网络药理学与实验验证相结合探索糖肾宁汤抗糖尿病肾病的潜在机制

Exploring the Potential Mechanism of Tang-Shen-Ning Decoction against Diabetic Nephropathy Based on the Combination of Network Pharmacology and Experimental Validation.

作者信息

Liang Jiajun, He Jiaxin, Gao Yanbin, Zhu Zhiyao

机构信息

School of Traditional Chinese Medicine, Capital Medical University, Beijing 100069, China.

Beijing Key Laboratory of TCM Collateral Disease Theory Research, Beijing 100069, China.

出版信息

Evid Based Complement Alternat Med. 2021 Sep 9;2021:1025053. doi: 10.1155/2021/1025053. eCollection 2021.

Abstract

BACKGROUND

Diabetic nephropathy (DN) has become one of the leading causes of the end-stage renal disease (ESRD). Tang-Shen-Ning (TSN) decoction, an effective Traditional Chinese formula for DN, can improve the renal function and inhibit renal fibrosis in DN. However, its potential mechanism is still unexplored.

METHODS

A network pharmacology approach was employed in this study, including screening for differential expressed genes of DN (DN-DEGs), protein-protein interaction (PPI) network analysis, and GO and KEGG enrichment analysis. Besides, a rat model was established to verify the potential effect of TSN in DN.

RESULTS

Twenty-three TSN-related DN-DEGs targets were identified. These genes were associated with decreased glomerular filtration rate (GFR) DN. The enrichment analysis suggested that the inhibition of renal fibrosis and inflammation through growth factors and chemokines is the potential mechanism through which TSN improves DN. TSN reduced renal fibrosis and improved pathological damage in the kidney in vivo through the regulation of GJA1, CTGF, MMP7, and CCL5, which are genes associated with ECM deposition.

CONCLUSION

This study revealed that TSN improves DN through a multicomponent, multitarget, and multipathway synergy. We provide a scientific basis for potential targets for TSN use to treat DN, yet further experimental validation is needed to investigate these targets and mechanisms.

摘要

背景

糖尿病肾病(DN)已成为终末期肾病(ESRD)的主要病因之一。糖肾宁(TSN)汤剂是一种治疗DN的有效中药方剂,可改善肾功能并抑制DN中的肾纤维化。然而,其潜在机制仍未被探索。

方法

本研究采用网络药理学方法,包括筛选DN的差异表达基因(DN-DEGs)、蛋白质-蛋白质相互作用(PPI)网络分析以及GO和KEGG富集分析。此外,建立大鼠模型以验证TSN对DN的潜在作用。

结果

鉴定出23个与TSN相关的DN-DEGs靶点。这些基因与肾小球滤过率(GFR)降低的DN相关。富集分析表明,通过生长因子和趋化因子抑制肾纤维化和炎症是TSN改善DN的潜在机制。TSN通过调节与细胞外基质(ECM)沉积相关的基因GJA1、CTGF、MMP7和CCL5,在体内减轻肾纤维化并改善肾脏病理损伤。

结论

本研究表明TSN通过多成分、多靶点和多途径协同作用改善DN。我们为TSN治疗DN的潜在靶点提供了科学依据,但仍需要进一步的实验验证来研究这些靶点和机制。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e746/8445713/0907bc6cb33d/ECAM2021-1025053.001.jpg

相似文献

3
Shen-Qi-Jiang-Tang granule ameliorates diabetic nephropathy via modulating tumor necrosis factor signaling pathway.
J Ethnopharmacol. 2023 Mar 1;303:116031. doi: 10.1016/j.jep.2022.116031. Epub 2022 Dec 8.
5
Network Pharmacology Analysis of ZiShenWan for Diabetic Nephropathy and Experimental Verification of Its Anti-Inflammatory Mechanism.
Drug Des Devel Ther. 2021 Apr 15;15:1577-1594. doi: 10.2147/DDDT.S297683. eCollection 2021.
6
Based on Network Pharmacology and Molecular Docking to Explore the Underlying Mechanism of Huangqi Gegen Decoction for Treating Diabetic Nephropathy.
Evid Based Complement Alternat Med. 2021 May 6;2021:9928282. doi: 10.1155/2021/9928282. eCollection 2021.
9
Uncovering the Mechanism of Astragalus membranaceus in the Treatment of Diabetic Nephropathy Based on Network Pharmacology.
J Diabetes Res. 2020 Mar 2;2020:5947304. doi: 10.1155/2020/5947304. eCollection 2020.

本文引用的文献

1
Pathophysiology of diabetic kidney disease: impact of SGLT2 inhibitors.
Nat Rev Nephrol. 2021 May;17(5):319-334. doi: 10.1038/s41581-021-00393-8. Epub 2021 Feb 5.
2
Network Pharmacology Approach to Explore the Potential Mechanisms of Jieduan-Niwan Formula Treating Acute-on-Chronic Liver Failure.
Evid Based Complement Alternat Med. 2020 Dec 30;2020:1041307. doi: 10.1155/2020/1041307. eCollection 2020.
4
PubChem in 2021: new data content and improved web interfaces.
Nucleic Acids Res. 2021 Jan 8;49(D1):D1388-D1395. doi: 10.1093/nar/gkaa971.
5
Potential Molecular Mechanisms of Chaihu-Shugan-San in Treatment of Breast Cancer Based on Network Pharmacology.
Evid Based Complement Alternat Med. 2020 Sep 25;2020:3670309. doi: 10.1155/2020/3670309. eCollection 2020.
7
An overview on the role of bioactive α-glucosidase inhibitors in ameliorating diabetic complications.
Food Chem Toxicol. 2020 Nov;145:111738. doi: 10.1016/j.fct.2020.111738. Epub 2020 Sep 9.
10
Pathogenic Pathways and Therapeutic Approaches Targeting Inflammation in Diabetic Nephropathy.
Int J Mol Sci. 2020 May 27;21(11):3798. doi: 10.3390/ijms21113798.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验